



Evolut Clinical Guideline 3099 for Carvykti™ (ciltacabtagene autoleucel)

Guideline Number: Evolut_CG_3099	<u>Applicable Codes</u>	
<i>"Evolut" refers to Evolut Health LLC and Evolut Specialty Services, Inc.</i> © 2022 - 2025 Evolut. All rights Reserved.		
Original Date: April 2022	Last Revised Date: November 2025	Implementation Date: November 2025

TABLE OF CONTENTS

STATEMENT	2
PURPOSE	2
INDICATIONS	2
MULTIPLE MYELOMA (MM).....	2
CONTRAINDICATIONS/WARNINGS	2
EXCLUSION CRITERIA	3
CODING AND STANDARDS	4
CODES.....	4
APPLICABLE LINES OF BUSINESS	4
POLICY HISTORY	5
LEGAL AND COMPLIANCE	5
GUIDELINE APPROVAL	5
Committee.....	5
DISCLAIMER	5
REFERENCES.....	5

STATEMENT

Purpose

To define and describe the accepted indications for Carvykti (ciltacabtagene autoleucl) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Multiple Myeloma (MM)

- Carvykti (ciltacabtagene autoleucl) may be used for adult members with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib) and an immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide), and are refractory to lenalidomide.

CONTRAINDICATIONS/WARNINGS

- US Boxed Warning
 - Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ciltacabtagene autoleucl. Do not administer ciltacabtagene autoleucl to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids.
 - Immune effector cell-associated neurotoxicity syndrome (ICANS), which may be fatal or life-threatening, occurred following treatment with ciltacabtagene autoleucl, including before CRS onset, concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after

treatment with ciltacabtagene autoleucl. Provide supportive care and/or corticosteroids as needed.

- Parkinsonism and Guillain-Barré syndrome (GBS) and their associated complications resulting in fatal or life-threatening reactions have occurred following treatment with ciltacabtagene autoleucl.
- Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with ciltacabtagene autoleucl. HLH/MAS can occur with CRS or neurologic toxicities.
- Prolonged and/or recurrent cytopenias with bleeding and infection and requirement for stem cell transplantation for hematopoietic recovery occurred following treatment with ciltacabtagene autoleucl.
- Secondary hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia, have occurred in patients following treatment with ciltacabtagene autoleucl. T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including ciltacabtagene autoleucl.
- Immune Effector Cell-associated Enterocolitis (IEC-EC), including fatal or life-threatening reactions, occurred following treatment with ciltacabtagene autoleucl.

EXCLUSION CRITERIA

- Disease progression on or after Carvykti (ciltacabtagene autoleucl) or prior treatment with chimeric antigen receptor T (CAR-T) therapy towards CD19 antigen (e.g., Abecma (idecabtagene vicleucl)].
- Concurrent use with other anti-myeloma therapy.
- Member does NOT have measurable disease defined as any of the following:
 - Serum monoclonal paraprotein (M-protein) level more than or equal to 1.0 g/dL or urine M-protein level greater than or equal to 200 mg/24hr OR
 - Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio.
- Does not exceed duration limit as one time administration.
- Dosing exceeds single dose limit of Carvykti (ciltacabtagene autoleucl) 1×10^8 CAR-positive viable T cells per single-dose infusion.
- Investigational use of Carvykti (ciltacabtagene autoleucl) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately

represented in the published evidence.

- Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
- Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
- That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
- That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
- That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- Q2056 - Ciltacabtagene autoleucl, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Applicable Lines of Business

<input type="checkbox"/>	CHIP (Children’s Health Insurance Program)
<input checked="" type="checkbox"/>	Commercial
<input checked="" type="checkbox"/>	Exchange/Marketplace
<input checked="" type="checkbox"/>	Medicaid
<input type="checkbox"/>	Medicare Advantage

POLICY HISTORY

Date	Summary
November 2025	<ul style="list-style-type: none"> Updated contraindications/warnings section by adding new Boxed Warning regarding the risk of immune effector cell-associated enterocolitis (IEC-EC), and removing Boxed Warning for REMS Updated references
May 2025	<ul style="list-style-type: none"> Converted to new Evolent guideline template This guideline replaces UM ONC_1460 Carvykti (ciltacabtagene autoleucl) Updated references
May 2024	<ul style="list-style-type: none"> Updated indication section Added new reference

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Services Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

- San-Miguel J, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. *N Engl J Med.* 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379.

2. Berdeja JG, et al. Ciltacabtagene autoleucl, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8.
3. Carvykti prescribing information. Janssen Biotech, Inc. Horsham, PA 2025.
4. Clinical Pharmacology Elsevier Gold Standard 2025.
5. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
6. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
7. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
8. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
9. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
10. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.